TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19001303

Group type: EXPERIMENTAL
Intervention: Automated telephone self-management support with nurse care management (ATSM)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 226
Study: 15925121

Group type: EXPERIMENTAL
Intervention: EWSRPT (Early Warning Signs Relapse Prevention Training)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: EWSRPT
Number of subjects: 124

Group type: COMPARATOR
Intervention: AU (Aftercare as Usual)
Number of subjects: 124
Study: 12545029

Group type: EXPERIMENTAL
Intervention: Endotracheal mechanical ventilation
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Predictors of endotracheal mechanical ventilation
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Vital capacity measurement
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Monitoring in intensive care unit
Number of subjects: 722
Study: 10886276

Group type: EXPERIMENTAL
Intervention: Topical 5% lidocaine cream (ELA-Max) with alexandrite 8 mm spot size
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Topical 5% lidocaine cream (ELA-Max) with alexandrite 12 mm spot size
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Topical 5% lidocaine cream (ELA-Max) with diode 9 mm spot size
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: No topical anesthesia with alexandrite 12 mm spot size
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: No topical anesthesia with diode 9 mm spot size
Number of subjects: 12

Group type: COMPARATOR
Intervention: Alexandrite laser
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 12
Study: 8778198

Group type: COMPARATOR
Intervention: Growth hormone (0.1 IU/kg per day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Triiodothyronine (40 micrograms on even dates, 20 micrograms on uneven dates)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Growth hormone + Triiodothyronine
Number of subjects: 8
Study: 1726002

Group type: EXPERIMENTAL
Intervention: 4 mg of lacidipine once daily (n = 268)
Number of subjects: 637

Group type: COMPARATOR
Intervention: 50 mg of atenolol once daily (n = 265)
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: 6 mg of lacidipine once daily (if needed)
Number of subjects: 637

Group type: COMPARATOR
Intervention: 100 mg of atenolol once daily (if needed)
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ, 25 mg once daily) added if required after 2 months
Number of subjects: 637
Study: 6432553

Group type: EXPERIMENTAL
Intervention: 100 mg bupropion hydrochloride orally with ethanol in orange drink
Number of subjects: 8

Group type: COMPARATOR
Intervention: 100 mg bupropion hydrochloride orally
Number of subjects: 8

Group type: COMPARATOR
Intervention: dummy tablet
Number of subjects: 8
Study: 31204799

Group type: EXPERIMENTAL
Intervention: Reflection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rationalization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ruminating on the moral status of impure acts
Number of subjects: 0
Study: 29895556

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 units/mL (Gla‐300)
Number of subjects: 1014

Group type: COMPARATOR
Intervention: Insulin glargine 100 units/mL (Gla‐100)
Number of subjects: 1014
Study: 27079985

Group type: EXPERIMENTAL
Intervention: Crisis plans (psychiatric advance statements)
Number of subjects: 139
Study: 24146086

Group type: EXPERIMENTAL
Intervention: Social norm message
Number of subjects: 260

Group type: COMPARATOR
Intervention: Standard instructions
Number of subjects: 260
Study: 22159672

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Risedronate (35 mg/week)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 19902241

Group type: EXPERIMENTAL
Intervention: Freight trains at 50 dBA (High)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Passenger trains at 50 dBA (High)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Automotive trains at 50 dBA (High)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Moderate noise level (40 dBA)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control night (silent)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Noise during REM sleep
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Age comparison (Juniors vs Seniors)
Number of subjects: 38
Study: 17563906

Group type: EXPERIMENTAL
Intervention: (18)F‐fluorodeoxyglucose (FDG)‐PET/CT
Number of subjects: 76
Study: 15781509

Group type: EXPERIMENTAL
Intervention: Peripheral nerve blocks (PNBs) with 2-chloroprocaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: General anesthesia (GA) with midazolam, fentanyl, propofol, N(2)O/O(2)/desflurane
Number of subjects: 50
Study: 12536163

Group type: EXPERIMENTAL
Intervention: Directional precue (left vs. right)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advance information
Number of subjects: 0
Study: 10648490

Group type: COMPARATOR
Intervention: Atrial overdrive alone
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Atrial overdrive + propafenone (600 mg/day)
Number of subjects: 22
Study: 8683752

Group type: EXPERIMENTAL
Intervention: Desmopressin (20 to 40 mcg)
Number of subjects: 95
Study: 1812146

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7051804

Group type: EXPERIMENTAL
Intervention: Early adjuvant chemotherapy (5-fluorouracil, cytoxan, and prednisone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed adjuvant chemotherapy (5-fluorouracil, cytoxan, and prednisone)
Number of subjects: 0
Study: 31232185

Group type: EXPERIMENTAL
Intervention: Tracking a sine wave template during training
Number of subjects: 12

Group type: COMPARATOR
Intervention: 30 additional trials of the target task (control)
Number of subjects: 12
Study: 30782863

Group type: EXPERIMENTAL
Intervention: Obesity intervention (specific details not provided)
Number of subjects: 69
Study: 25259737

Group type: EXPERIMENTAL
Intervention: Multivitamin and mineral preparation (single dose)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Multivitamin and mineral preparation with guaraná (single dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study: 25552402

Group type: COMPARATOR
Intervention: Sublingual asenapine 5 mg after ≥ 10 h fasting (Treatment A, reference)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sublingual asenapine 5 mg after a high‐fat meal (Treatment B)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sublingual asenapine 5 mg after ≥ 10 h fasting with a high‐fat meal at 4 h post‐dose (Treatment C)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sublingual asenapine 5 mg after a high‐fat meal at 4 h post-dose (Treatment C)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sublingual asenapine 5 mg after a high‐fat meal (Treatment B) and after ≥ 10 h fasting with a high‐fat meal at 4 h post-dose (Treatment C)
Number of subjects: 26
Study: 23687405

Group type: EXPERIMENTAL
Intervention: CACFP participation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-participating centers (Control)
Number of subjects: 0
Study: 21367594

Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg once-daily
Number of subjects: 1123

Group type: COMPARATOR
Intervention: Salmeterol 50 μg twice-daily
Number of subjects: 1123
Study: 19411954

Group type: EXPERIMENTAL
Intervention: Cerebral palsy group (CP)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Cerebral palsy group (CP) with intellectual disability (ID)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Cerebral palsy group (CP) without intellectual disability (ID)
Number of subjects: 125
Study: 17116685

Group type: EXPERIMENTAL
Intervention: Three antimalarial treatments
Number of subjects: 141
Study: 15296910

Group type: EXPERIMENTAL
Intervention: Thoracoscopic mechanical pleurodesis (TMP)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Talc pleurodesis (TP)
Number of subjects: 87
Study: 11747326

Group type: EXPERIMENTAL
Intervention: Nurse-led care
Number of subjects: 115
Study: 9089939

Group type: EXPERIMENTAL
Intervention: Posterior lumbar interbody fusion with BAK
Number of subjects: 75

Group type: COMPARATOR
Intervention: 360 degrees fusion
Number of subjects: 75
Study: 8506440

Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 to 5 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Atenolol 50 to 100 mg
Number of subjects: 53

Group type: COMPARATOR
Intervention: ABPM (Ambulatory Blood Pressure Monitoring)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Self-assessment of blood pressure
Number of subjects: 53

Group type: COMPARATOR
Intervention: Diastolic ambulatory daily values
Number of subjects: 53
Study: 3552917

Group type: EXPERIMENTAL
Intervention: 5% ethanolamine oleate (EO)
Number of subjects: 34

Group type: COMPARATOR
Intervention: 1% Aethoxysklerol (AS)
Number of subjects: 34
Study: 29194927

Group type: EXPERIMENTAL
Intervention: Computer guided sinus floor elevation through lateral window approach with simultaneous implant placement
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard sinus elevation procedure through lateral window approach with simultaneous implant placement
Number of subjects: 20
Study: 27565012

Group type: EXPERIMENTAL
Intervention: Acute dose of alcohol (0.8 g/kg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 24845208

Group type: EXPERIMENTAL
Intervention: Eccentric Resistance Training (ERT)
Number of subjects: 60
Study: 22324529

Group type: EXPERIMENTAL
Intervention: Non-interference protocol
Number of subjects: 167

Group type: COMPARATOR
Intervention: Interference protocol
Number of subjects: 167
Study: 20484246

Group type: EXPERIMENTAL
Intervention: SNP microarray-based aneuploidy screening (n = 85)
Number of subjects: 13

Group type: COMPARATOR
Intervention: FISH-based aneuploidy screening (n = 75)
Number of subjects: 13
Study: 19000028

Group type: EXPERIMENTAL
Intervention: DHEA therapy
Number of subjects: 918

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 918
Study: 16953457

Group type: EXPERIMENTAL
Intervention: Finasteride 1 mg co-administered with omeprazole 20 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Omeprazole 20 mg alone
Number of subjects: 24
Study: 14610995

Group type: EXPERIMENTAL
Intervention: Patient-centered advice message
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Video doctor technology
Number of subjects: 52
Study: 10913033

Group type: EXPERIMENTAL
Intervention: Intermittent exercise at 40% maximum voluntary contraction (MVC)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intermittent exercise at 20% maximum voluntary contraction (MVC)
Number of subjects: 31
Study: 8923853

Group type: COMPARATOR
Intervention: Group A (constant dose 4 IU/m2 b.s.)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Group B (4-6-6-6 IU/m2 b.s.)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Group C (4-6-8-8 IU/m2 b.s.)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 65
Study: 1279169

Group type: EXPERIMENTAL
Intervention: Intravenous iloprost
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 3905218

Group type: EXPERIMENTAL
Intervention: Diclofenac SR 100 mg/day
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg/day
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 29879602

Group type: EXPERIMENTAL
Intervention: Antipsychotic blood levels (ABLs)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No antipsychotic blood levels (ABLs)
Number of subjects: 34
Study: 26444072

Group type: EXPERIMENTAL
Intervention: ITI-007 60 mg
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 335

Group type: COMPARATOR
Intervention: ITI-007 120 mg
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: ITI-007 60 mg and 120 mg
Number of subjects: 335
Study: 25748317

Group type: EXPERIMENTAL
Intervention: Haptic supplementation with a mobile stick on a rough surface
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Haptic supplementation with a mobile stick on a slippery surface
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Fixed stick condition
Number of subjects: 11

Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 11
Study: 23743471

Group type: EXPERIMENTAL
Intervention: Buccal misoprostol (400 micrograms)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Synthetic osmotic cervical dilator
Number of subjects: 125
Study: 20652004

Group type: EXPERIMENTAL
Intervention: GM-CSF treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 17645503

Group type: EXPERIMENTAL
Intervention: Annual screens by gynecological examination (sequential pelvic ultrasound [US] and serum CA125 test)
Number of subjects: 41688

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 41688
Study: 16153914

Group type: COMPARATOR
Intervention: Normal saline (n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nicardipine, 0.5 microg x kg x min (n = 9)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nitroglycerin, 0.5 microg x kg x min (n = 11)
Number of subjects: 30
Study: 12580267

Group type: EXPERIMENTAL
Intervention: 25 microg/kg(‐1) of droperidol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 150 microg/kg(‐1) of ondansetron
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 120
Study: 9874808

Group type: EXPERIMENTAL
Intervention: Celecoxib (100, 400, or 800 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibuprofen (800 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Celecoxib (100-800 mg)
Number of subjects: 0
Study: 8684687

Group type: EXPERIMENTAL
Intervention: Heparan sulfate
Number of subjects: 30
Study: 1904891

Group type: EXPERIMENTAL
Intervention: Encainide or Flecainide
Number of subjects: 2371

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2371
Study: 6352448

Group type: EXPERIMENTAL
Intervention: Sheath technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Free-hand technique
Number of subjects: 40
Study: 30784839

Group type: EXPERIMENTAL
Intervention: Hybrid simulation (HS)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Simulation with birth model (SBM)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Video demonstration (VD)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 82
Study: 28903767

Group type: EXPERIMENTAL
Intervention: Pessary containing amphoteric tenside (WO3191) after metronidazole treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pessary containing lactic acid (Control)
Number of subjects: 0
Study: 26965694

Group type: EXPERIMENTAL
Intervention: Continuous erythropoiesis receptor activator (C.E.R.A.) once-monthly
Number of subjects: 2060
Study: 25318787

Group type: EXPERIMENTAL
Intervention: Remedial hydration (RH)
Number of subjects: 216

Group type: COMPARATOR
Intervention: No remedial hydration (control)
Number of subjects: 216
Study: 22074122

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg once daily for 24 weeks
Number of subjects: 170

Group type: COMPARATOR
Intervention: Amlodipine 10 mg once daily for 24 weeks
Number of subjects: 170
Study: 19765769

Group type: EXPERIMENTAL
Intervention: Potassium citrate (20 mEq) ingested daily by International Space Station crew members
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30
Study: 17472097

Group type: EXPERIMENTAL
Intervention: Self-activation before the IAT categorization task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Implicit Association Test (IAT)
Number of subjects: 0
Study: 15260460

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 128

Group type: COMPARATOR
Intervention: No vaccination (Control)
Number of subjects: 128
Study: 12171961

Group type: EXPERIMENTAL
Intervention: Ileoanal reservoir (IAR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control tissue (ileal)
Number of subjects: 40
Study: 11743486

Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 436

Group type: COMPARATOR
Intervention: Chlorhexidine 0.1%
Number of subjects: 436
Study: 9429034

Group type: EXPERIMENTAL
Intervention: Hospital-made diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Commercial diet
Number of subjects: 20
Study: 8508666

Group type: EXPERIMENTAL
Intervention: Norethisterone acetate 1000 micrograms + ethinyloestradiol 30 micrograms
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 150 micrograms + ethinyloestradiol 30 micrograms
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Desogestrel 150 micrograms + ethinyloestradiol 30 micrograms
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Gestodene 75 micrograms + ethinyloestradiol 30 micrograms
Number of subjects: 131
Study: 2872808

Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Terazosin with beta blocker plus diuretic
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo with beta blocker plus diuretic
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Terazosin with other antihypertensive drugs
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo with other antihypertensive drugs
Number of subjects: 138
Study: 31969547

Group type: EXPERIMENTAL
Intervention: High-frequency (HF) group: Nanoseal application at baseline and 1-5 months
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Low-frequency (LF) group: Nanoseal application at baseline and 3 months
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group: no application of Nanoseal
Number of subjects: 129
Study: 29081255

Group type: EXPERIMENTAL
Intervention: Benda‐14 (intravenous bendamustine, 120 mg/m2 on days 1 and 15, repeated every 4 weeks for a total of 6 cycles)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 46
Study: 27732620

Group type: EXPERIMENTAL
Intervention: Embedded Figures Test (EFT)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Simulation groups (control, naïve simulation, symptom-coached simulation, test-coached simulation)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: EFT index for prediction of feigned ADHD
Number of subjects: 371
Study: 24630880

Group type: EXPERIMENTAL
Intervention: bare Cheatham-Platinum stents (bCP)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: covered Cheatham-Platinum stents (cCP)
Number of subjects: 120
Study: 22433939

Group type: EXPERIMENTAL
Intervention: Low-dose oxytocin
Number of subjects: 144

Group type: COMPARATOR
Intervention: Dinoprostone vaginal pessary (Propess®)
Number of subjects: 144
Study: 20551234

Group type: EXPERIMENTAL
Intervention: Computer‐assisted personal interview (CAPI)
Number of subjects: 2351

Group type: EXPERIMENTAL
Intervention: Computer‐assisted self‐interview (CASI)
Number of subjects: 2351

Group type: COMPARATOR
Intervention: Pen and paper interview (PAPI)
Number of subjects: 2351
Study: 18789533

Group type: COMPARATOR
Intervention: Distance activities during 2 hours of daily patching
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Near activities during 2 hours of daily patching
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Both groups (Distance and Near activities)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: 2 hours of daily patching (for children with severe amblyopia)
Number of subjects: 425
Study: 15910489

Group type: EXPERIMENTAL
Intervention: Octreotide (0.75 microg/kg/h for 3 h after a bolus of 0.75 microg/kg body weight)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 14
Study: 12578430

Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10499694

Group type: EXPERIMENTAL
Intervention: Point of Care Testing (PCT)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Central Laboratory Testing
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Point of Care Testing (PCT) among discharged patients
Number of subjects: 180

Group type: COMPARATOR
Intervention: Central Laboratory Testing among admitted patients
Number of subjects: 180
Study: 9180977

Group type: EXPERIMENTAL
Intervention: Oral ondansetron (4 mg) administered 1 hour before induction and additional doses at 8 and 16 hours later
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral metoclopramide (5 mg) administered under the same conditions
Number of subjects: 30
Study: 1918565

Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ADHD boys
Number of subjects: 15
Study: 31812457

Group type: EXPERIMENTAL
Intervention: Retroactive Interference (RI) manipulation task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control task (simple guilty)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (RI and control)
Number of subjects: 0
Study: 31309929

Group type: EXPERIMENTAL
Intervention: ClientBot (immediate feedback on use of open questions and reflections)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (initial education and encouragement on the skills)
Number of subjects: 151
Study: 28019072

Group type: EXPERIMENTAL
Intervention: gemigliptin
Number of subjects: 132

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 132
Study: 27436289

Group type: EXPERIMENTAL
Intervention: Patient education programme delivered by GPs after a 2-day interactive workshop
Number of subjects: 241

Group type: COMPARATOR
Intervention: Routine care (Control Group)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Patient education programme delivered by GPs
Number of subjects: 241
Study: 24404816

Group type: EXPERIMENTAL
Intervention: Telemonitoring arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care arm
Number of subjects: 0
Study: 23029969

Group type: EXPERIMENTAL
Intervention: Deep breathing exercise at 6 breaths/min (0.1 Hz) for one month
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no breathing exercise)
Number of subjects: 36
Study: 18634717

Group type: EXPERIMENTAL
Intervention: 25 En% casein-custard
Number of subjects: 25

Group type: COMPARATOR
Intervention: 10 En% casein-custard
Number of subjects: 25
Study: 17499470

Group type: EXPERIMENTAL
Intervention: Quetiapine (QUE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clozapine (CLO) as internal standard
Number of subjects: 0